230 related articles for article (PubMed ID: 21814779)
41. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
42. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
Oh PJ; Lee JR; Kim SK; Kim JH
Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
[TBL] [Abstract][Full Text] [Related]
43. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
Schüll B; Scheithauer W
Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
[TBL] [Abstract][Full Text] [Related]
44. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Vatandoust S; Joshi R; Pittman KB; Esterman A; Broadbridge V; Adams J; Singhal N; Yeend S; Price TJ
Support Care Cancer; 2014 Feb; 22(2):513-8. PubMed ID: 24122404
[TBL] [Abstract][Full Text] [Related]
45. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
46. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.
Brennan BP; Fogarty KV; Roberts JL; Reynolds KA; Pope HG; Hudson JI
Hum Psychopharmacol; 2009 Jul; 24(5):423-8. PubMed ID: 19548294
[TBL] [Abstract][Full Text] [Related]
47. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Cathomas R; Köberle D; Ruhstaller T; Mayer G; Räss A; Mey U; von Moos R
Support Care Cancer; 2010 Oct; 18(10):1263-70. PubMed ID: 19756772
[TBL] [Abstract][Full Text] [Related]
48. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
50. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache.
Volpe FM
J Clin Psychiatry; 2008 Sep; 69(9):1449-54. PubMed ID: 19193344
[TBL] [Abstract][Full Text] [Related]
51. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
Aziz MT; Good BL; Lowe DK
Ann Pharmacother; 2014 May; 48(5):626-32. PubMed ID: 24577146
[TBL] [Abstract][Full Text] [Related]
52. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
53. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
54. Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine.
Schneider E; Linden M; Weigmann H; Wagner T; Quail D; Hundemer HP; Hegerl U
BMC Psychiatry; 2011 Sep; 11():150. PubMed ID: 21933428
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
[TBL] [Abstract][Full Text] [Related]
56. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
57. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
Matsuoka H; Makimura C; Koyama A; Otsuka M; Okamoto W; Fujisaka Y; Kaneda H; Tsurutani J; Nakagawa K
Anticancer Res; 2012 May; 32(5):1805-9. PubMed ID: 22593465
[TBL] [Abstract][Full Text] [Related]
58. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.
Fishbain DA; Detke MJ; Wernicke J; Chappell AS; Kajdasz DK
Curr Med Res Opin; 2008 Nov; 24(11):3105-15. PubMed ID: 18828958
[TBL] [Abstract][Full Text] [Related]
59. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N; Alavi A; Heydarheydari S; Moradian N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
[TBL] [Abstract][Full Text] [Related]
60. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
